Literature DB >> 20488469

The Swedish reflux trial in children: II. Vesicoureteral reflux outcome.

Gundela Holmdahl1, Per Brandström, Göran Läckgren, Ulla Sillén, Eira Stokland, Ulf Jodal, Sverker Hansson.   

Abstract

PURPOSE: We compared reflux status in children with dilating vesicoureteral reflux treated in 3 groups, including low dose antibiotic prophylaxis, endoscopic therapy and a surveillance group on antibiotic treatment only for febrile urinary tract infection.
MATERIALS AND METHODS: A total of 203 children 1 to younger than 2 years with grade III-IV reflux were recruited into this open, randomized, controlled trial. Endoscopic treatment was done with dextranomer/hyaluronic acid copolymer. The main end point was reflux status after 2 years. Data were analyzed by the intent to treat principle.
RESULTS: Reflux status improved in all 3 treatment arms. Of patients in the prophylaxis, endoscopic and surveillance groups 39%, 71% and 47%, respectively, had reflux resolution or downgrading to grade I-II after 2 years. This was significantly more common in the endoscopic than in the prophylaxis and surveillance groups (p = 0.0002 and 0.0030, respectively). After 1 or 2 injections 86% of patients in the endoscopic group had no or grade I-II reflux but recurrent dilating reflux was seen in 20% after 2 years.
CONCLUSIONS: Endoscopic treatment resulted in dilating reflux resolution or downgrading in most treated children. After 2 years endoscopic treatment results were significantly better than the spontaneous resolution rate or downgrading in the prophylaxis and surveillance groups. However, of concern is the common reappearance of dilating reflux after 2 years. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488469     DOI: 10.1016/j.juro.2010.01.059

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  35 in total

Review 1.  [Therapeutic options for primary vesicoureteral reflux: endoscopic vs open surgical approach].

Authors:  C Ziesel; S Frees; J W Thüroff; R Stein
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

2.  Rebuttal.

Authors:  Armando J Lorenzo
Journal:  Can Urol Assoc J       Date:  2010-08       Impact factor: 1.862

3.  [Treatment of vesicoureteral reflux in childhood].

Authors:  I Körner; J Steffens
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

Review 4.  [Current and practice-relevant news from pediatric urology].

Authors:  R Stein; A Schröder; M Goepel
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

Review 5.  [Vesicoureteral reflux: diagnostics and therapy].

Authors:  W H Rösch; V Geyer
Journal:  Urologe A       Date:  2011-06       Impact factor: 0.639

6.  Modified STING procedure for high-grade vesicoureteral reflux in children: intraureteral injection with ureteral orifice reposition technique.

Authors:  Takao Fujimoto; Tomohide Suwa; Nozomi Ishii
Journal:  Pediatr Surg Int       Date:  2012-08-03       Impact factor: 1.827

7.  Parental Preference Assessment for Vesicoureteral Reflux Management in Children.

Authors:  Geraldine N Tran; Anand V Bodapati; Jonathan C Routh; Christopher S Saigal; Hillary L Copp
Journal:  J Urol       Date:  2016-12-11       Impact factor: 7.450

8.  Different imaging strategies in febrile urinary tract infection in childhood. What, when, why?

Authors:  Diego De Palma; Gianantonio Manzoni
Journal:  Pediatr Radiol       Date:  2013-03-24

9.  A comparison of the double hydrodistention implantation technique (HIT) and the HIT with a polyacrylate/polyalcohol copolymer (PPC) for the endoscopic treatment of primary vesicoureteral reflux.

Authors:  Melih Akin; Basak Erginel; Cetin Ali Karadag; Abdullah Yildiz; Gül Sumru Ozçelik; Nihat Sever; Nimetullah Mete Genc; Ali Ihsan Dokucu
Journal:  Int Urol Nephrol       Date:  2014-06-26       Impact factor: 2.370

10.  NICE guidelines for imaging studies in children with UTI adequate only in boys under the age of 6 months.

Authors:  Marko Tapani Ristola; Timo Hurme
Journal:  Pediatr Surg Int       Date:  2013-01-13       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.